Groupe Francophone Des Myelodysplasies — Sponsor Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

3 Recruiting

8 Completed trials

3 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase I (Other)

Phase III: 1 Phase II: 5 Phase I/II: 3 Phase I (Other): 1

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Myelodysplastic syndrome 1 VEXAS syndrome 1

Top IMPs

AZACITIDINE 5 VENETOCLAX 3 EPOETIN ALFA 2 ARSENIC TRIOXIDE 1 DECITABINE, CEDAZURIDINE 1 ENASIDENIB MESILATE 1 IVOSIDENIB 1 LUSPATERCEPT 1 MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE 1

All trials

10 total

Momelotinib in VEXAS syndrome Recruiting

2024-519779-24-00 Phase II 1 country MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
Oral arsenic (ATO) in low-risk myelodysplastic syndromes (MDS) failing Erythropoiesis Stimulating Agents and Luspatercept Recruiting

2024-515311-22-00 Phase I (Other) 1 country ARSENIC TRIOXIDE
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Phase I/II 2 countries EPOETIN ALFA; LUSPATERCEPT
Study of safety and efficacy of ONUREG in combination with VENETOCLAX in higher-risk myelodysplastic syndromes ineligible for allogenic tran… Ended

2024-514876-41-00 Phase I/II 1 country AZACITIDINE; VENETOCLAX
Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) Ended

2024-514878-53-00 Phase II 1 country AZACITIDINE; VENETOCLAX
Study of the safety and efficacy of treatment venetoclax + azacitidine and donor lymphocyte infusion in patients with MDS or AML in relapse … Ended

2024-514877-23-00 Phase I/II 1 country AZACITIDINE; VENETOCLAX
Study of the efficacy of treatment with AG-120 in patients with Myelodysplastic Syndrome and mutation IDH1 Ended

2024-515352-20-00 Phase II 1 country AZACITIDINE; IVOSIDENIB
study of the efficacy of treatment with AG-221 in patients with myelodysplastic syndrome and mutation IDH2 Ended

2024-513858-29-01 Phase II 2 countries AZACITIDINE; ENASIDENIB MESILATE
ASTX727 AND DONOR LYMPHOCYTE INFUSIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN VERY HIGH RISK MDS OR AML PATIENTS Ended

2024-515353-24-00 Phase II 1 country DECITABINE, CEDAZURIDINE
A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WI… Ended

2024-515356-21-00 Phase III 1 country EPOETIN ALFA

Showing 1–10 of 10 trials

← All sponsors A–Z